← Leaderboards
William A. Garland
Centaur Pharmaceuticals, Inc.
$1,958,794
Attributed
$2,958,730
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1M · FY2010–18$2M$1.5M$1M$500K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$2,958,730 · 5
By mechanism
R44$2,371,080 · 2
R43$587,650 · 3
Top collaborators
- Jeffrey H Thomas2 shared
Most similar at Centaur Pharmaceuticals, Inc.
Same institution · by research overlap
- Kirk R Maples$200,000
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsCancer PatientFundingBaseInhibitor/AntagonistPhenotypeGrantGenesSmall Business Innovation Research GrantTumorSafetyPharmaceutical PreparationsSafety StudyResponseSmall MoleculeIn VivoDesignLocationGuanosine Triphosphate PhosphohydrolasesColorectal CancerGrowthErbituxEpidermal Growth Factor ReceptorCetuximab
Grant awards (6)
Suppressors of kRAS Activity Discovered Using a Fruit Fly-based In-vivo Screen$956,150
R44 · FY2018 · CA · contact PI
Suppressors of kRAS Activity Discovered Using a Fruit Fly-based In-vivo Screen$1,043,722
R44 · FY2017 · CA · contact PI
Screening with D. melanogaster to Discover Inhibitors G12V Mutated kRAS$225,000
R43 · FY2014 · CA · contact PI
Anchored Antioxidants to Provide Increased Protective Effect$199,500
R43 · FY2010 · HL · contact PI
Studies in Mice to Improve Efficacy/Safety of Paclitaxel/Docetaxel with an Anti-I$163,150
R43 · FY2010 · CA · contact PI
NRTS AS THERAPEUTICS FOR INFLAMMATORY BOWEL DISEASE$371,208
R44 · FY2001 · DK